GlassScriptPhysician profile
Ralph Cipriano
NPI 1821541442
$5,817.35
in general payments reported to CMS, 2019-2025
22 companies · $2,191 in 2025
The $2,191 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $684 · 2021: $606 · 2022: $751 · 2023: $336 · 2024: $789 · 2025: $2,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248 · Travel and Lodging: $812 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.59 |
| Travel and Lodging | $811.98 |
| Education | $256.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,926.86 | 2022-2025 | General - Vascular Access, Avvigo Guidance System, Wolverine Coronary Cutting Balloon |
| Abbott Laboratories | $577.32 | 2022-2025 | Diamondback Coronary, Xience Skypoint, Na |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $458.73 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $415.76 | 2019-2022 | |
| Astellas Pharma US INC | $346.42 | 2019-2021 | |
| Shockwave Medical, INC | $320.88 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.24 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $232.60 | 2020-2025 | |
| Amgen INC. | $224.75 | 2020-2025 | Repatha |
| Chiesi USA, INC. | $219.34 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $181.70 | 2020-2025 | Eliquis, Camzyos |
| Abiomed | $123.47 | 2020 | |
| Akcea Therapeutics, INC. | $121.32 | 2019 | |
| Medtronic, INC. | $113.13 | 2022-2025 | Symplicity G3, Corevalve Evolut R |
| Lantheus Medical Imaging, INC. | $73.10 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $59.71 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $41.83 | 2021-2024 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $37.20 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $21.57 | 2025 | Arexvy, Shingrix |
| Scpharmaceuticals INC. | $18.27 | 2024 | |
| Inspire Medical Systems, INC. | $18.14 | 2025 | Inspire |
| Siemens Medical Solutions USA, INC. | $13.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Cipriano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.